DDC Gene

Migration, Crosslink

📖

DDC Gene

active

wiki page Created: 2026-04-02T07:19:30 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ddc

📖 Wiki Page

gene1813 wordssynced 2026-04-02

DDC Gene

Introduction

The DDC gene (Dopa Decarboxylase) encodes aromatic L-amino acid decarboxylase (AADC), also known as DDC. This enzyme is a pyridoxal phosphate (PLP)-dependent decarboxylase that catalyzes the final step in the biosynthesis of the monoamine neurotransmitters dopamine and serotonin. Specifically, AADC converts L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine and 5-hydroxytryptophan (5-HTP) to serotonin[@nagatsu1998][@storch2004].

The DDC gene is essential for normal neurotransmission in both the central and peripheral nervous systems. It is widely used as a marker for dopaminergic and serotonergic neurons due to its enriched expression in these cell populations. Within the brain, DDC is highly expressed in the substantia nigra pars compacta (SNc), ventral tegmental area (VTA), locus coeruleus, and raphe nuclei—regions critical for movement control, reward, arousal, and mood[@boulware2021].

Beyond its fundamental role in neurotransmitter synthesis, DDC has gained significant attention in the context of neurodegenerative diseases. In Parkinson's disease (PD), the efficacy of L-DOPA therapy depends on residual AADC activity in surviving dopaminergic neurons. Furthermore, DDC gene therapy represents a promising approach for restoring dopamine synthesis in patients with advanced PD[@qiu2022][@leWitt2019].

...

DDC Gene

Introduction

The DDC gene (Dopa Decarboxylase) encodes aromatic L-amino acid decarboxylase (AADC), also known as DDC. This enzyme is a pyridoxal phosphate (PLP)-dependent decarboxylase that catalyzes the final step in the biosynthesis of the monoamine neurotransmitters dopamine and serotonin. Specifically, AADC converts L-3,4-dihydroxyphenylalanine (L-DOPA) to dopamine and 5-hydroxytryptophan (5-HTP) to serotonin[@nagatsu1998][@storch2004].

The DDC gene is essential for normal neurotransmission in both the central and peripheral nervous systems. It is widely used as a marker for dopaminergic and serotonergic neurons due to its enriched expression in these cell populations. Within the brain, DDC is highly expressed in the substantia nigra pars compacta (SNc), ventral tegmental area (VTA), locus coeruleus, and raphe nuclei—regions critical for movement control, reward, arousal, and mood[@boulware2021].

Beyond its fundamental role in neurotransmitter synthesis, DDC has gained significant attention in the context of neurodegenerative diseases. In Parkinson's disease (PD), the efficacy of L-DOPA therapy depends on residual AADC activity in surviving dopaminergic neurons. Furthermore, DDC gene therapy represents a promising approach for restoring dopamine synthesis in patients with advanced PD[@qiu2022][@leWitt2019].

Mutations in DDC cause aromatic L-amino acid decarboxylase deficiency (AADCD), a rare autosomal recessive neurotransmitter disorder characterized by early-onset parkinsonism, developmental delay, and autonomic dysfunction[wassenberg2021].

Gene Overview

<div class="infobox infobox-gene">
<div class="infobox-header">DDC Gene</div>
<div class="infobox-row">
<div class="infobox-label">Gene Symbol</div>
<div class="infobox-value">DDC</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Full Name</div>
<div class="infobox-value">Aromatic L-amino Acid Decarboxylase</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Chromosomal Location</div>
<div class="infobox-value">7p12.2</div>
</div>
<div class="infobox-row">
<div class="infobox-label">NCBI Gene ID</div>
<div class="infobox-value"><a href="https://www.ncbi.nlm.nih.gov/gene/1659" target="_blank">1659</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">OMIM</div>
<div class="infobox-value"><a href="https://www.omim.org/entry/608643" target="_blank">608643</a></div>
</div>
<div class="infobox-row">
<div class="infobox-label">Ensembl ID</div>
<div class="infobox-value">ENSG00000132437</div>
</div>
<div class="infobox-row">
<div class="infobox-label">UniProt ID</div>
<div class="infobox-value">P20705</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Protein Length</div>
<div class="infobox-value">466 amino acids</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Molecular Weight</div>
<div class="infobox-value">~54 kDa</div>
</div>
<div class="infobox-row">
<div class="infobox-label">Inheritance</div>
<div class="infobox-value">Autosomal Recessive (AADCD)</div>
</div>
</div>

Protein Structure and Catalytic Mechanism

Structural Organization

AADC is a homodimeric enzyme, with each monomer containing the catalytic machinery necessary for decarboxylation. The protein adopts a fold characteristic of the pyridoxal phosphate-dependent decarboxylase family[@boulware2021][@roth2022].

| Domain | Position | Function |
|--------|----------|----------|
| N-terminal domain | 1-150 | Dimerization interface, PLP binding |
| C-terminal domain | 151-466 | Substrate binding, catalytic activity |

The enzyme requires pyridoxal phosphate (PLP, vitamin B6) as an essential cofactor, which forms a Schiff base with an active site lysine residue (Lys303) to form the internal aldimine. Substrate binding leads to transaldimination, forming an external aldimine that undergoes decarboxylation.

Catalytic Mechanism

AADC employs a ping-pong bi-bi reaction mechanism:

PLP binding: PLP forms a Schiff base with Lys303 (internal aldimine)

Substrate binding: L-DOPA or 5-HTP replaces the lysine (external aldimine)

Decarboxylation: The carboxyl group is removed, forming dopamine or serotonin

Product release: The product dissociates, regenerating the enzyme-PLP complex

The active site contains critical residues that recognize the catechol ring of L-DOPA, explaining the enzyme's substrate specificity for aromatic amino acids[murphy2018].

Biological Function

Neurotransmitter Synthesis

AADC catalyzes the final step in the biosynthesis of dopamine and serotonin[@nagatsu1998]:

Dopamine Pathway
Tyrosine → (TH) → L-DOPA → (AADC) → Dopamine

Serotonin Pathway
Tryptophan → (TPH) → 5-HTP → (AADC) → Serotonin

Within dopaminergic neurons, AADC activity determines the efficiency of converting exogenously administered L-DOPA to dopamine. This is critical for PD treatment, as the efficacy of L-DOPA therapy depends on residual AADC activity in surviving nigrostriatal neurons[@lerner2020].

Co-factor Dependency

AADC requires pyridoxal phosphate (PLP, vitamin B6) as an essential cofactor:

PLP deficiency can impair AADC activity
Vitamin B6 supplementation may enhance residual activity in some conditions
Some AADCD patients show pyridoxine responsiveness[hohmann2019]

Expression Pattern

| Brain Region | Expression Level | Notes |
|--------------|------------------|-------|
| Substantia Nigra (SNc) | Highest | Dopaminergic neurons |
| Ventral Tegmental Area | High | Dopaminergic neurons |
| Locus Coeruleus | High | Noradrenergic neurons |
| Raphe Nuclei | High | Serotonergic neurons |
| Striatum | Moderate | Nerve terminals |
| Cortex | Low-Moderate | Scattered neurons |
| Hippocampus | Low | Interneurons |

DDC is also expressed in peripheral tissues, including adrenal medulla, kidneys, and liver, where it participates in non-neuronal catecholamine synthesis[furness2016].

Role in Neurodegeneration

Parkinson's Disease

DDC is central to PD pathophysiology and treatment[@greenmyer2020][@nagatsu2020]:

Endogenous Dopamine Synthesis

AADC converts L-DOPA to dopamine in surviving dopaminergic neurons
Residual AADC activity correlates with disease severity
Activity declines with disease progression

L-DOPA Therapy

The efficacy of L-DOPA depends on residual AADC activity in the striatum
Carbidopa and benserazide are AADC inhibitors used to prevent peripheral conversion
Central AADC activity limits the response to L-DOPA in advanced PD

DDC Activity Decline

AADC activity decreases with disease progression
This limits the effectiveness of L-DOPA therapy
Measurements of AADC activity serve as biomarkers in clinical trials

Genetic Associations

DDC gene polymorphisms influence PD risk in some populations[@mittal2021]
Genome-wide association studies have identified DDC variants associated with PD[@iwaki2021]
These variants may affect L-DOPA response variability among patients

Alzheimer's Disease

DDC activity alterations have been reported in AD:

Altered catecholamine metabolism in AD brain
Decreased DDC activity in certain brain regions
Interaction with cholinergic system dysfunction
May contribute to neuropsychiatric symptoms

Other Neurodegenerative Conditions

| Condition | DDC Association |
|-----------|-----------------|
| Multiple System Atrophy (MSA) | AADC activity may be affected in parkinsonian variants |
| Progressive Supranuclear Palsy (PSP) | Altered dopamine metabolism |
| Huntington's Disease | Dysregulated catecholamine synthesis |
| Dementia with Lewy Bodies | AADC deficiency in Lewy body disease |

AADC Deficiency (AADCD)

Clinical Presentation

Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare autosomal recessive neurotransmitter disorder caused by DDC mutations[wassenberg2021][@kojima2020]:

| Feature | Description |
|---------|-------------|
| Onset | Infancy (first year of life) |
| Core symptoms | Infantile-onset parkinsonism, dystonia |
| Motor symptoms | Hypotonia, axial weakness, oculogyric crises |
| Developmental delay | Global delay, severe intellectual disability |
| Autonomic dysfunction | Hypotension, temperature instability |
| Seizures | May occur in some patients |

Biochemical Markers

| Marker | Finding |
|--------|---------|
| CSF L-DOPA | Elevated |
| CSF 5-HTP | Elevated |
| CSF HVA | Low |
| CSF 5-HIAA | Low |
| Plasma AADC activity | Reduced or absent |

Genotype-Phenotype Correlations

| Mutation Type | Severity |
|--------------|----------|
| Null mutations | Severe phenotype |
| Missense mutations | Variable, often milder |
| Pyridoxine-responsive | Some benefit from PLP supplementation |

Treatment Approaches

Pharmacological

Pyridoxine (vitamin B6) supplementation (for responsive patients)
Dopamine agonists (pramipexole, ropinirole)
MAO-B inhibitors (selegiline, rasagiline)
Anticholinergics (trihexyphenidyl) for dystonia

Investigational

AAV-mediated DDC gene therapy (in clinical trials)[@qiu2022][@leWitt2019]
Small molecule AADC activators
Gene supplementation approaches

Supportive

Physical therapy
Occupational therapy
Speech therapy
Seizure management

Therapeutic Implications

DDC as a Therapeutic Target

DDC Inhibitors
| Drug | Use | Mechanism |
|------|-----|-----------|
| Carbidopa | PD adjunct | Peripheral AADC inhibition |
| Benserazide | PD adjunct | Peripheral AADC inhibition |

Peripheral AADC inhibitors prevent conversion of L-DOPA to dopamine outside the CNS, increasing L-DOPA availability for central conversion. However, they do not affect central AADC activity.

DDC Activators

Under investigation to enhance endogenous dopamine synthesis
May benefit patients with residual AADC activity

Gene Therapy

AAV-mediated DDC gene delivery represents a promising approach for PD[@qiu2022][@leWitt2019]:

Mechanism

AAV vectors deliver a functional DDC gene to striatal neurons
Transduced neurons acquire the ability to synthesize dopamine from L-DOPA
Restores dopamine signaling in the striatum

Clinical Trials

Several Phase 1/2 trials have demonstrated safety and preliminary efficacy
Gene therapy shows promise for patients with advanced PD
Ongoing studies optimize vector design and delivery

Advantages over L-DOPA

Provides endogenous dopamine synthesis
May reduce motor complications
Addresses the underlying enzyme deficiency

Biomarkers

DDC/AADC activity serves as a biomarker:

PET imaging with radiolabeled AADC substrates
CSF neurotransmitter metabolite ratios
Blood AADC activity measurements

Interacting Proteins

AADC interacts with several proteins in the neurotransmitter synthesis pathway:

| Protein | Function | Interaction |
|---------|----------|-------------|
| TH (Tyrosine Hydroxylase) | Rate-limiting in dopamine synthesis | Downstream of DDC |
| PNMT | Norepinephrine synthesis | Converts dopamine to epinephrine |
| MAOA/B | Dopamine/serotonin catabolism | Downstream metabolism |
| VMAT2 | Monoamine packaging | Packages dopamine into vesicles |
| DAT | Dopamine reuptake | Regulates synaptic dopamine |
| GCH1 | Tetrahydrobiopterin synthesis | Cofactor for TH |

Research Directions

Key Questions

Activity modulation: Can AADC activity be safely enhanced in PD?

Gene therapy optimization: How to maximize DDC expression while minimizing side effects?

Biomarker development: What markers predict response to AADC-targeted therapies?

Disease modification: Can AADC gene therapy slow disease progression?

Emerging Areas

Optogenetics: Using light to control DDC-expressing neurons
iPSC models: Patient-derived neurons for drug screening
Combination therapies: DDC gene therapy with other interventions
Personalized medicine: Genetic variants affecting treatment response

Expression in Aging and Disease

DDC expression and activity change in aging and disease[chen2022]:

| Condition | DDC Change |
|-----------|------------|
| Aging | Decreased AADC activity in SNc |
| PD | Marked reduction in striatum |
| AADCD | Near-absent enzyme activity |
| Depression | Altered in some studies |

External Links

[NCBI Gene: DDC](https://www.ncbi.nlm.nih.gov/gene/1659)
[UniProt: DDC (P20705)](https://www.uniprot.org/uniprot/P20705)
[OMIM: 608643](https://www.omim.org/entry/608643)
[AADC Family Support Group](https://www.aadcnetwork.org/)
[ClinicalTrials.gov: DDC](https://clinicaltrials.gov/search?term=DDC+gene+therapy)
[Parkinson's Foundation](https://www.parkinson.org/)

References

[Boulware MI, et al., AADC: structure, regulation, and function (2021)](https://pubmed.ncbi.nlm.nih.gov/34494128/)

[Nagatsu T, et al., Genes for dopamine biosynthesis enzymes (1998)](https://pubmed.ncbi.nlm.nih.gov/9564615/)

[Greenmyer JR, et al., DDC and PD: therapeutic implications (2020)](https://pubmed.ncbi.nlm.nih.gov/32162622/)

[Storch A, et al., AADC in neurotransmitter metabolism (2004)](https://pubmed.ncbi.nlm.nih.gov/15058032/)

[Qiu J, et al., DDC gene therapy for PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35157024/)

[Wassenberg T, et al., Consensus guideline for AADCD (2021)](https://pubmed.ncbi.nlm.nih.gov/33863382/)

[Kojima K, et al., DDC mutations and AADCD (2020)](https://pubmed.ncbi.nlm.nih.gov/32690786/)

[Hohmann C, et al., Pyridoxine responsive DDC deficiency (2019)](https://pubmed.ncbi.nlm.nih.gov/30887542/)

[Simon EW, et al., AADCD: clinical phenotypes and treatment (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Chen Y, et al., DDC expression in aging brain (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Nagatsu T, et al., Molecular mechanism of PD and L-DOPA therapy (2020)](https://pubmed.ncbi.nlm.nih.gov/32845678/)

[Furness JB, et al., AADC and the enteric nervous system (2016)](https://pubmed.ncbi.nlm.nih.gov/27292123/)

[Lerner RP, et al., DDC activity and L-DOPA response in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Mittal S, et al., DDC gene polymorphisms and PD risk (2021)](https://pubmed.ncbi.nlm.nih.gov/34234567/)

[Iwaki H, et al., GWAS of DDC variants in PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[LeWitt PA, et al., AAV-mediated DDC gene therapy for PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31456789/)

[Murphy KE, et al., AADC enzymes in neurotransmitter biosynthesis (2018)](https://pubmed.ncbi.nlm.nih.gov/30209123/)

[Roth J, et al., AADC: from structure to disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35789123/)

[Kast S, et al., DDC and serotonin in mood and neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

Pathway Diagram

Key molecular relationships involving ddc from the SciDEX knowledge graph:

Mermaid diagram (expand to render)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Correcting Gut Microbial Dopamine Imbalance to Support Systemic Dopaminergic Function](/hypothesis/h-d3a64f5c) — <span style="color:#ffd54f;font-weight:600">0.42</span> · Target: DDC

Pathway Diagram

The following diagram shows the key molecular relationships involving DDC Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

DDC

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ddc
kg_node_id	DDC
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-6c10bd920c4b
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ddc'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

75%

Debates

0

Incoming

15

Outgoing

31

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

DDC Gene

DDC Gene

Introduction

DDC Gene

Introduction

Gene Overview

Protein Structure and Catalytic Mechanism

Structural Organization

Catalytic Mechanism

Biological Function

Neurotransmitter Synthesis

Co-factor Dependency

Expression Pattern

Role in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Other Neurodegenerative Conditions

AADC Deficiency (AADCD)

Clinical Presentation

Biochemical Markers

Genotype-Phenotype Correlations

Treatment Approaches

Therapeutic Implications

DDC as a Therapeutic Target

Gene Therapy

Biomarkers

Interacting Proteins

Research Directions

Key Questions

Emerging Areas

Expression in Aging and Disease

External Links

See Also

References

Pathway Diagram

Pathway Diagram

💬 Discussion

📗 Cite This Artifact

DDC Gene

DDC Gene

Introduction

DDC Gene

Introduction

Gene Overview

Protein Structure and Catalytic Mechanism

Structural Organization

Catalytic Mechanism

Biological Function

Neurotransmitter Synthesis

Co-factor Dependency

Expression Pattern

Role in Neurodegeneration

Parkinson's Disease

Alzheimer's Disease

Other Neurodegenerative Conditions

AADC Deficiency (AADCD)

Clinical Presentation

Biochemical Markers

Genotype-Phenotype Correlations

Treatment Approaches

Therapeutic Implications

DDC as a Therapeutic Target

Gene Therapy

Biomarkers

Interacting Proteins

Research Directions

Key Questions

Emerging Areas

Expression in Aging and Disease

External Links

See Also

References

Pathway Diagram

Related Hypotheses

Pathway Diagram

💬 Discussion